Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial (Q42399878)

29 October 2017

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial (English)

1 reference

chronic lymphocytic leukemia

29 October 2017

phase II clinical trial

0 references

0 references

1 reference

1 reference

1 reference

David E Spaner

1

1 reference

29 October 2017

Guizhei Wang

2

1 reference

29 October 2017

Lindsay McCaw

3

1 reference

29 October 2017

Yanmei Li

4

1 reference

29 October 2017

Patricia Disperati

5

1 reference

29 October 2017

Mary-Ann Cussen

6

1 reference

29 October 2017

Yonghong Shi

7

1 reference

29 October 2017

27 January 2016

1 reference

29 October 2017

1 reference

29 October 2017

101

1 reference

29 October 2017

5

1 reference

29 October 2017

e192-5

1 reference

Targeted therapies in CLL: mechanisms of resistance and strategies for management

29 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Chronic lymphocytic leukemia in less fit patients: "slow-go".

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5004376

Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26819050

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26819050

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26819050

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2015.135418

1 reference

29 October 2017

1 reference

29 October 2017

1 reference